We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 198

Double brevet toujours pertinent?
  • Norton Rose Fulbright LLP
  • Canada
  • August 14 2015

La Loi sur les brevets stipule que le titulaire d’un brevet n’a droit qu’à un brevet pour une seule invention . Ce principe d’apparence simple a


En brevets, le critère d’évidence n’est pas évident à définir
  • Norton Rose Fulbright Canada LLP
  • Canada
  • August 10 2015

Confirmant la décision de la Cour fédérale, dans l’affaire E. Mishan & Sons, Inc. v. Supertek Canada Inc., 2015 FCA 163, la Cour d’appel fédérale a


Pharma in brief - non-infringing alternative (NIA) defence may be relevant in patent damages quantification: “could” and “would” an NIA have been used?
  • Norton Rose Fulbright Canada LLP
  • Canada
  • August 6 2015

In the liability phase, the Federal Court (FC) found that Canadian Patent No. 1,161,380 (380 Patent) was valid and infringed by Apotex. In the


Pharma in brief - Federal Court of Appeal relaxes the “perfect match” requirement for patent listing under the Patented Medicines (Notice of Compliance) Regulations
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 28 2015

The Minister of Health refused to list a patent on the Patent Register in respect of a fixed-dose combination product because it did not contain a


Pharma in brief - Federal Court of Appeal finds that “promised” utility need not be coterminous with the inventive concept
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 27 2015

AstraZeneca Canada Inc. (AstraZeneca) appealed from the decision of Justice Rennie of the Federal Court (reported as AstraZeneca Canada Inc. v


Du nouveau concernant le programme Premier brevet!
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 20 2015

En octobre 2013, le gouvernement du Québec annonçait la création du programme Premier brevet découlant de la Politique nationale de la recherche


Pharma in brief - Apotex Inc. and Apotex Pharmachem Inc. are ordered to disgorge profits in excess of $61 million
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 10 2015

Apotex Inc. (Apotex) and Apotex Pharmachem Inc. (Pharmachem) have been ordered by the Federal Court to pay to Adir and Servier Canada


Pharma in brief - Federal Court applies principle of claim differentiation and rejects elevated “promise” of utility for compound claims
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 8 2015

O’Reilly J. granted a prohibition order sought by Novartis Pharmaceuticals Canada Inc. (Novartis) under section 6 of thePM(NOC) Regulations against


IP monitor - a controversial diagnosis: new patent examination guidance in Canada for evaluating diagnostic methods
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 7 2015

On June 29, 2015, the Canadian Intellectual Property Office issued guidance to patent examiners on examining patent applications for medical


Pharma in brief - Federal Court recommendations on “increased proportionality in complex litigation” impact Canadian pharmaceutical patent litigation
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 3 2015

The Federal Court issued a Notice to the Parties and the Profession dated June 24, 2015 (the "Notice") containing its initial recommendations